We are live on ! Find out more
LEXX icon

Lexaria Bioscience
LEXX

12 hedge funds and large institutions have $1.85M invested in Lexaria Bioscience in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

9% more funds holding

Funds holding: 11 → 12 (+1)

1.17% less ownership

Funds ownership: 8.86% → 7.69% (-1.2%)

35% less capital invested

Capital invested by funds: $2.83M → $1.85M (-$978K)

Holders
12
Holders Change
+1
Holders Change %
+9.09%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ICM
Invenomic Capital Management
Massachusetts
+$38.1K
2
UBS Group
UBS Group
Switzerland
+$23.6K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$18.7K
4
Osaic Holdings
Osaic Holdings
Arizona
+$9.47K
5
TRCT
Tower Research Capital (TRC)
New York
+$6.83K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$75K
2
Morgan Stanley
Morgan Stanley
New York
-$5.72K

LEXX Hedge Fund Activity: Q4 2021 in Review

12 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q4 2021, worth a combined $1.85M — down 35% from $2.83M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new LEXX positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 0 trimmed.

The largest buyer was Invenomic Capital Management, adding an estimated $38.1K. The largest seller was Virtu Financial, exiting entirely with an estimated $75K sold.

  • 12 institutional investors held Lexaria Bioscience (LEXX) as of Q4 2021, up from 11 in Q3 2021.
  • Funds reported $1.85M of Lexaria Bioscience stock for Q4 2021, down 35% quarter-over-quarter.
  • 3 funds opened new Lexaria Bioscience positions in Q4 2021 and 2 closed out, a net change of +1 holder.
  • The largest Lexaria Bioscience buyer in Q4 2021 was Invenomic Capital Management, an estimated $38.1K added.
  • The largest Lexaria Bioscience seller in Q4 2021 was Virtu Financial, an estimated $75K sold.

Based on aggregated 13F filings for Q4 2021.